

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representation of  
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**



5413

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/10, C12Q 1/68	A1	(11) International Publication Number: WO 98/41623 (43) International Publication Date: 24 September 1998 (24.09.98)
(21) International Application Number: PCT/DK98/00105 (22) International Filing Date: 18 March 1998 (18.03.98) (30) Priority Data: 0304/97 18 March 1997 (18.03.97) DK 0432/97 17 April 1997 (17.04.97) DK (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2350 Bagsværd (DK). (72) Inventors: BORCHERT, Torben, Vedel; Smakkevej 1, DK-4040 Jyllinge (DK). KRETZSCHMAR, Tirus; Kasperlmühlstrasse 6, D-81739 Munich (DE). CHERRY, Joel, R.; 915 Anderson Road, Davis, CA 95616 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO <del>patent</del> : (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian <del>patent</del> : (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European <del>patent</del> : (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI <del>patent</del> (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published With international search report.	
(54) Title: SHUFFLING OF HETEROLOGOUS DNA SEQUENCES		
(57) Abstract <p>The present invention relates to a new method of shuffling especially heterologous polynucleotide sequences, screening and/or selection of new recombinant proteins resulting therefrom having a desired biological activity, and especially to production and identification of novel proteases exhibiting desired properties. The method comprises the following steps; i) identification of at least one conserved region between the heterologous sequences of interest; ii) generating fragments of each of the heterologous sequences of interest, wherein said fragments comprise the conserved region(s), in a preferred embodiment due to the use of parts of the region(s) as primers; and iii) shuffling/recombining said fragments using the conserved region(s) as (s) homologous linking point(s).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CC	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE: Shuffling of heterologous DNA sequences

FIELD OF THE INVENTION

The present invention relates to a new method of shuffling  
5 especially heterologous polynucleotide sequences, screening and/or  
selection of new recombinant proteins resulting therefrom having a  
desired biological activity, and especially to the production and  
identification of novel proteases exhibiting desired properties.

10 BACKGROUND OF THE INVENTION

It is generally found that a protein performing a certain  
bioactivity exhibits a certain variation between genera, and even  
between members of the same species differences may exist. This  
variation is even more outspoken at the genomic level.

15 This natural genetic diversity among genes coding for pro-  
teins having basically the same bioactivity has been generated in  
nature over billions of years and reflects a natural optimisation  
of the proteins coded for in respect of the environment of the or-  
ganism in question.

20 However, in general it has been found that the naturally oc-  
curring bioactive molecules are not optimized for the various uses  
to which they are put by mankind, especially when they are used  
for industrial purposes.

It has therefore been of interest to industry to identify  
25 such bioactive proteins that exhibit optimal properties in respect  
of the use for which it is intended.

This has been done for many years by screening of natural  
sources, or by use of mutagenesis. For instance, within the tech-  
nical field of enzymes for use in e.g. detergents, the washing  
30 and/or dishwashing performance of e.g. naturally occurring prote-  
ases, lipases, amylases and cellulases has been improved signifi-  
cantly by *in vitro* modifications of the enzymes.

In most cases these improvements have been obtained by site-  
directed mutagenesis resulting in substitution, deletion or inser-  
35 tion of specific amino acid residues which have been chosen either  
on the basis of their type or on the basis of their location in  
the secondary or tertiary structure of the mature enzyme (see for  
instance US patent no. 4,518,584).

Prior Art:

Numerous methods to create genetic diversity, such as by site directed or random mutagenesis, have been proposed and described in scientific literature as well as patent applications. For further details in this respect reference is made to the related art section of WO 95/22625, wherein a review is provided.

One method of the shuffling of homologous DNA sequences has been described by Stemmer (Stemmer, (1994), Proc. Natl. Acad. Sci. USA, Vol. 91, 10747-10751; Stemmer, (1994), Nature, vol. 370, 389-391). The method concerns shuffling homologous DNA sequences by using *in vitro* PCR techniques. Positive recombinant genes containing shuffled DNA sequences are selected from a DNA library based on the improved function of the expressed proteins.

WO 95/22625 is believed to be the most pertinent reference in relation to the present invention in its "gene shuffling" aspect. In WO 95/22625 a method for shuffling of homologous DNA sequences is described. An important step in the method described in WO 95/22625 is to cleave the homologous template double-stranded polynucleotide into random fragments of a desired size followed by homologically reassembling of the fragments into full-length genes.

A disadvantage inherent to the method of WO 95/22625 is, however, that the diversity generated through that method is limited due to the use of homologous gene sequences (as defined in WO 95/22625).

Another disadvantage in the method of WO 95/22625 lies in the production of the random fragments by the cleavage of the template double-stranded polynucleotide.

A further reference of interest is WO 95/17413 describing a method of gene or DNA shuffling by recombination of DNA sequences either by recombination of synthesized double-stranded fragments or recombination of PCR generated sequences. According to the method described in WO 95/17413 the recombination has to be performed among DNA sequences with sufficient sequence homology to enable hybridization of the different sequences to be recombined.

WO 95/17413 therefore also entails the disadvantage that the diversity generated is relatively limited.

The present invention does not contain any steps involving production of random fragments by the cleavage of the template double-stranded polynucleotide, as described in WO 95/22625.

Further, WO 95/22625 relates to shuffling of homologous genes, while the present invention relates to shuffling of heterologous genes.

**SUMMARY OF THE INVENTION:**

The problem to be solved by the present invention is to avoid the limitation of shuffling only homologous DNA sequences by providing a method to shuffle/recombine heterologous sequences of interest.

The solution is to use at least one "conserved sequence region", wherein there is a sufficient degree of homology between the heterologous sequences to be shuffled, as a "linking point" between said heterologous sequences.

Accordingly, a first aspect of the invention relates to a method of shuffling of heterologous sequences of interest comprising the following steps,

- i) identification of at least one conserved region between the heterologous sequences of interest;
- ii) generating fragments of each of the heterologous sequences of interest, wherein said fragments comprise the conserved region(s); and
- iii) shuffling/recombining said fragments using the conserved region(s) as (a) homologous linking point(s).

In an second aspect the invention relates to a method for producing a shuffled protein having a desired biological activity comprising in addition to the steps of the first aspect the further steps:

- iv) expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences from step iii); and
- v) screen or select the numerous different recombinant proteins from step ii) in a suitable screening or selection system for one or more recombinant protein(s) having a desired activity.

The term "conserved region" denotes a sequence region (preferably of at least 10 bp), wherein there is a relatively high sequence identity between said heterologous sequences.

5 In order for the conserved region to be used as "linking point" between said heterologous sequences, the sequence identity between the heterologous sequences, within said conserved regions, is sufficiently high to enable hybridization of the heterologous sequences using said conserved region as hybridization point  
10 ("linking point").

#### BRIEF DESCRIPTION OF DRAWINGS

Fig. 1: Fig 1 illustrates the general concept of the invention,  
15 where

- a) the black boxes define mutual, common, conserved regions of the sequences of interest, and
- b) the PCR primers named "a, a', b, b', etc.." are primers directed to the conserved regions. Primers ("a'" and "b"), ("b'" and  
20 "c") etc.. have a sequence overlap of preferably at least 10 bp, and
- c) primers "z" and "z'" are primers directed to the flanking parts of the sequence area of the sequences of interest which are shuffled according to the method of the invention.

25

Fig 2: Shows an alignment of 5 protease (subtilase) DNA sequences. Herein are a number of conserved regions such as the common partial sequences numbered 1-5.

30 Fig 3: Shows an alignment of different lipases.

#### DEFINITIONS

Prior to discussing this invention in further detail, the following terms will be defined.

35 "Shuffling": The term "shuffling" means recombination of nucleotide sequence(s) between two or more DNA sequences of interest resulting in output DNA sequences (i.e. DNA sequences having been subjected to a shuffling cycle) having a number of nucleo-



tides exchanged, in comparison to the input DNA sequences (i.e. starting point DNA sequences of interest).

Alternatively, the term "shuffling" may be termed "recombining".

5 "Homology of DNA sequences": In the present context the degree of DNA sequence homology is determined as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin  
10 Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin; USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453).

"Homologous": The term "homologous" means that one single-  
15 stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later  
20 (*vide infra*).

Using the computer program GAP (*vide supra*) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, it is in the present context believed that two DNA sequences will be able to hybridize (using  
25 medium stringency hybridization conditions as defined below) if they mutually exhibit a degree of identity of at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 85%, and even more preferably at least 90%.

30 "Heterologous": Two DNA sequences are said to be heterologous if one of them comprises a partial sequence of at least 40 bp which does not exhibit a degree of identity of more than 50%, more preferably of more than 70%, more preferably of more than 80%, more preferably of more than 85%, more preferably of more than  
35 90%, and even more preferably of more than 95%, of any partial sequence in the other. More preferably the first partial sequence is at least 60 bp, more preferably the first partial sequence is at least 80 bp, even more preferably the first partial sequence is at

least 120 bp, and most preferably the first partial sequence is at least 500 bp.

"Hybridization:" Suitable experimental conditions for determining if two or more DNA sequences of interest do hybridize or not are herein defined as hybridization at medium stringency as described in detail below.

A suitable experimental low stringency hybridization protocol between two DNA sequences of interest involves presoaking of a filter containing the DNA fragments to hybridize in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 µg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a concentration of 10ng/ml of a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) Anal. Biochem. 132:6-13), 32P-dCTP-labeled (specific activity > 1 x 10<sup>9</sup> cpm/µg ) probe (DNA sequence) for 12 hours at approx. 45°C. The filter is then washed twice for 30 minutes in 2 x SSC, 0.5 % SDS at least 55°C, more preferably at least 60°C, and even more preferably at least 65°C (high stringency).

Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using an X-ray film.

"Alignment": The term "alignment" used herein in connection with an alignment of a number of DNA and/or amino acid sequences means that the sequences of interest are aligned in order to identify mutual/common sequences of homology/identity between the sequences of interest. This procedure is used to identify common "conserved regions" (vide infra), between sequences of interest. An alignment may suitably be determined by means of computer programs known in the art, such as PILEUP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453).

"Conserved regions:" The term "conserved region" used herein in connection with a "conserved region" between DNA and/or amino acid sequences of interest means a mutual, common sequence region

of two or more sequences of interest, wherein there is a relatively high degree of sequence identity between two or more of the heterologous sequences of interest. In the present context a conserved region is preferably at least 10 base pairs (bp), more preferably at least 20 bp, and even more preferably at least 30 bp.

Using the computer program GAP (*vide supra*) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the degree of DNA sequence identity within the conserved region, between two or more of the heterologous sequences of interest, is preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and even more preferably at least 95%.

"Primer": The term "primer" used herein, especially in connection with a PCR reaction, is a primer (especially a "PCR-primer") defined and constructed according to general standard specification known in the art ("PCR A practical approach" IRL Press, (1991)).

"A primer directed to a sequence": The term "a primer directed to a sequence" means that the primer (preferably to be used in a PCR reaction) is constructed so as to exhibit at least 80% degree of sequence identity to the sequence part of interest, more preferably at least 90% degree of sequence identity to the sequence part of interest, which said primer consequently is "directed to".

"Sequence overlap extension PCR reaction (SOE-PCR)": The term "SOE-PCR" is a standard PCR reaction protocol known in the art, and in the present context it is defined and performed according to standard protocols defined in the art ("PCR A practical approach" IRL Press, (1991)).

"Flanking": The term "flanking" used herein in connection with DNA sequences comprised in a PCR-fragment means the outmost end partial sequences of the PCR-fragment, both in the 5' and 3' ends of the PCR fragment.

"Subtilases": A serine protease is an enzyme which catalyzes the hydrolysis of peptide bonds, and in which there is an essential serine residue at the active site (White, Handler and Smith,

1973 "Principles of Biochemistry," Fifth Edition, McGraw-Hill Book Company, NY, pp. 271-272).

The bacterial serine proteases have molecular weights in the range of 20,000 to 45,000 Daltons. They are inhibited by diisopropylfluorophosphate. They hydrolyze simple terminal esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease. A more narrow term, alkaline protease, covering a sub-group, reflects the high pH optimum of some of the serine proteases, from pH 9.0 to 11.0 (for review, see Priest (1977) Bacteriological Rev. 41 711-753).

A sub-group of the serine proteases tentatively designated subtilases has been proposed by Siezen et al., Protein Engng. 4 (1991) 719-737. They are defined by homology analysis of more than 40 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases.

#### DETAILED DESCRIPTION OF THE INVENTION

##### A method for shuffling heterologous sequences of interest

In a preferred embodiment the fragments generated in step ii) of the first aspect of the invention is generated by use of PCR technology.

Accordingly, an aspect of the invention relates to a method of shuffling of heterologous DNA sequences of interest, according to the first aspect of the invention, comprising the following steps

- i) identification of one or more conserved region(s) (hereafter named "A,B,C" etc..) in two or more of the heterologous sequences;
- ii) construction of at least two sets of PCR primers (each set comprising a sense and an anti-sense primer) for one or more conserved region(s) identified in i) wherein
  - in one set the sense primer (named: "a"=sense primer) is directed to a sequence region 5' (sense strand) of said conserved region (e.g. conserved region "A"), and the anti-sense primer (named "a'"=anti-sense primer) is directed either to a sequence region 3' (sense strand) of said conserved region or directed to a

- sequence region at least partially within said conserved region,  
and in another set the sense primer (named: "b"=sense primer) is directed either to a sequence region 5' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region and the anti-sense primer (named: "b'"=anti-sense primer) is directed to a sequence region 3' (sense strand) of said conserved region (e.g. conserved region "A"), and  
the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions is including the actual primer sequences) have a homologous sequence overlap of at least 10 base pairs (bp) within the conserved region;
- iii) for one or more identified conserved regions of interest in step i) two PCR amplification reactions are performed with the heterologous DNA sequences in step i) as template, and where
- one of the PCR reactions uses the 5' primer set identified in step ii) (e.g. named "a","a'") and the second PCR reaction uses the 3' primer set identified in step ii) (e.g. named "b","b'");
- iv) isolation of the PCR fragments generated as described in step iii) for one or more of the identified conserved region in step i);
- v) pooling of two or more isolated PCR fragments from step iv) and performing a Sequence overlap extension PCR reaction (SOE-PCR) using said isolated PCR fragments as templates; and
- vi) isolation of the PCR fragment obtained in step v), wherein said isolated PCR fragment comprises numerous different shuffled sequences containing a shuffled mixture of the PCR fragments isolated in step iv), wherein said shuffled sequences are
- characterized in that the partial DNA sequences, originating from the homologous sequence overlaps in step ii), have at least 80%

identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

A method of producing one or more recombinant protein(s) having a  
5 desired biological activity

In a second aspect the invention relates to a method of producing a shuffled protein having a desired biological activity comprising in addition to the steps i) to vi) immediately above the further steps:

- 10 vii) expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences in step vi); and
- viii) screen or select the numerous different recombinant proteins from step vii) in a suitable screening or selection system for one or more recombinant protein(s)  
15 having a desired activity.

Heterologous DNA sequences

The method of the present invention may be used to shuffle  
20 basically all heterologous DNA sequences of interest.

Preferably, it is used to shuffle heterologous DNA sequences encoding an enzymatic activity, such as amylase, lipase, cutinase, cellulase, oxidase, phytase, and protease activity.

An further advantage of the present method is that it makes  
25 it possible to shuffle heterologous sequences encoding different activities, e.g. different enzymatic activities.

The method of the invention is in particular suitable to shuffle heterologous DNA sequences encoding a protease activity, in particular a subtilase activity.

30 A number of subtilase DNA sequences are published in the art. A number of those subtilase DNA sequences are in the present context heterologous DNA sequences, and it is generally believed that they are mutually too heterologous to be shuffled by the shuffling methods presently known in the art (WO 95/17413, WO  
35 95/22625). However the method according to the invention enables shuffling of such sequences. For further details reference is made to a working example herein (vide infra).

Further, the present invention is suitable to shuffle different lipase sequences. For further details reference is made to a working example herein (*vide infra*).

The heterologous DNA sequences used as templates may beforehand have been cloned into suitable vectors, such as a plasmid. Alternatively, a PCR-reaction may be performed directly on microorganisms known to comprise the DNA sequence of interest according to standard PCR protocols known in the art.

10 Identification of one or more conserved regions in heterologous sequences:

Identification of conserved regions may be done by an alignment of the heterologous sequences by standard computer programs (*vide supra*).

15 Alternatively, the method may be performed on completely new sequences, where the relevant "conserved regions" are chosen as conserved regions which are known in the art to be conserved regions for this particular class of proteins.

E.g., the method may be used to shuffle completely unknown  
20 subtilase sequences, which are known to be very conserved in e.g. regions around the active site amino acids. PCR reaction may then be performed directly on new unknown strains with primers directed to those conserved regions.

25 PCR-primers

The PCR primers are constructed according to the standard descriptions in the art. Preferably, they are 10-75 base pairs (bp) long.

30 Homologous sequence overlap

In step ii) of claim 3 of the invention the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions is including the actual primer sequences) have a homologous sequence overlap of at least 10 base  
35 pairs (bp) within the conserved region.

Said homologous sequence overlap is more preferably of at least 15 bp, more preferably of at least 20 bp, and even more preferably of at least 35 bp.

The homologous sequence overlaps in step ii) of claim 3 have at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i) of said claim, more preferably the homologous sequence overlaps in step 5 ii) have at least 90% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i) of said claim, and even more preferably the homologous sequence overlaps in step ii) have at least 95% identity to one or more partial sequences in one or more of the original heterologous DNA 10 sequences in step i) of said claim.

#### PCR-reactions

If not otherwise mentioned the PCR-reaction performed according to the invention is performed according to standard proto- 15 cols known in the art.

The term "Isolation of PCR fragment" is intended to cover an aliquot containing the PCR fragment. However, the PCR fragment is preferably isolated to an extent which removes surplus of primers, nucleotides, etc.

20 Further, the fragment used for SOE-PCR in step v) of claim 3, may alternatively be generated by other processes than the PCR amplification process described in step iii) of said claim. Suitable fragments used for the SOE-PCR in step v), may e.g. be generated by cutting out suitable fragments by restriction enzyme di- 25 gestion at appropriate sites (e.g. restriction sites situated on each site of a conserved region identified in step i). Such alternative processes for generating such suitable fragments for use in the SOE-PCR in step v) are considered within the scope of the invention.

30 In an embodiment of the invention the PCR DNA fragment(s) is(are) prepared under conditions resulting in a low, medium or high random mutagenesis frequency.

To obtain low mutagenesis frequency the DNA sequence(s) (comprising the DNA fragment(s)) may be prepared by a standard PCR 35 amplification method (US 4,633,202 or Saiki et al., (1988), Science 239, 487 - 491).

A medium or high mutagenesis frequency may be obtained by performing the PCR amplification under conditions which increase



the misincorporation of nucleotides, for instance as described by Deshler, (1992), GATA 9(4), 103-106; Leung et al., (1989), Technique, Vol. 1, No. 1, 11-15.

#### 5 Final shuffled sequences

One of the advantages of the present invention is that the final "shuffled sequences" in step vi) of claim 3 of the present invention only comprise sequence information which is originally derived from the original heterologous sequences of interest in  
10 step i) of said claim. The present invention does not use artificially made "linker sequences" to recombine one or more of the heterologous sequences, which is a strategy known in the art to e.g. be able to shuffle different domains in proteins, wherein each domain is encoded by different heterologous sequences (WO  
15 95/17413).

Accordingly, the invention relates to a method characterized in that each of the shuffled sequences, the partial DNA sequences, originating from the homologous sequence overlaps in step ii), only contains sequence information which is originally derived  
20 from the original heterologous sequences in step i) (in the first to third aspect of the invention) (i.e. said "homologous sequence overlaps" in step ii) has at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

25 More preferably, the "homologous sequence overlaps" in step ii) have at least 90% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i); and even more preferably the "homologous sequence overlaps" in step ii) have at least 95% identity to one or more partial se-  
30 quences in one or more of the original heterologous DNA sequences in step i), and most preferably the "homologous sequence overlaps" in step ii) have 100% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

#### 35 Expressing the recombinant protein from the shuffled sequences

Expression of the recombinant protein encoded by the shuffled sequence of the present invention may be performed by use of

standard expression vectors and corresponding expression systems known in the art.

Suitable screening or selection system

5 In its second aspect the present invention relates to a method for producing one or more recombinant protein(s) having a desired biological activity.

A suitable screening or selection system will depend on the desired biological activity.

10 A number of suitable screening or selection systems to screen or select for a desired biological activity are described in the art. Examples are:

Strauberg et al. (Biotechnology 13: 669-673 (1995), which describes a screening system to screen for subtilisin variants  
15 having a calcium-independent stability;

Bryan et al. (Proteins 1:326-334 (1986)), which describes a screening assay to screen for proteases having enhanced thermal stability; and

WO 97/04079 which describes a screening assay to screen for  
20 lipases having an improved wash performance in washing detergents.

A preferred embodiment of the invention comprises screening or selection of recombinant protein(s), wherein the desired biological activity is performance in dish-washing or laundry detergents. Examples of suitable dish-washing or laundry detergents are  
25 disclosed in WO 97/04079 and WO 95/30011.

The invention is described in further detail in the following examples which are not in any way intended to limit the scope of the invention.

30 MATERIALS AND METHODS

Strains

E. coli strain: DH10B (Life Technologies)

35 Bacillus subtilis strain: DM1885 amyE. A derivative of B,s  
168RUB200 (J. Bacteriology 172:4315-4321 (1990))

### Plasmids

pKH400: pKH400 was constructed from pJS3 (E. coli - B. subtilis shuttle vector containing a synthetic gene encoding for subtilase 309 (described by Jacob Schiødt et al. in Protein and Peptide letters 3:39-44 (1996)), by introduction of two BamHI sites at positions 1841 and 3992.

### Protease sequences used for shuffling

GenBank entries A13050\_1, D26542, A22550, Swiss-Prot entry  
10 SUBT\_BACAM P00782, and PD498 (Patent Application No. WO 96/34963).

### General molecular biology methods

Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular  
15 biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons,  
20 1990).

Enzymes for DNA manipulations were used according to the specifications of the suppliers.

### Enzymes for DNA manipulations

25 Unless otherwise mentioned all enzymes for DNA manipulations, such as e.g. restriction endonucleases, ligases etc., are obtained from New England Biolabs, Inc.

### EXAMPLES

30

#### EXAMPLE 1

##### A) Vector construction

35 1) Amplification of the pre-pro sequences

Host cells harboring the plasmid DNA encoding the full length enzymes A13050\_1 (GenBank), SUBT\_BACAM P00782 (Swiss-Prot), D26542 (GenBank), A22550 (GenBank), and PD498 (Patent Application No. WO

96/34963) were starting material. By standard mini-prep isolation of plasmid DNA, purified DNA was obtained. With these template DNAs, 5 standard PCRs were performed to amplify the respective pre-pro sequences. The fragments were generated using the proof reading Pwo DNA polymerase (Boehringer Mannheim) and the following sets of primers directed against the very N- and C-termini of the respective pre-pro sequences:

## A13050\_1

10 TiK111: 5' GAG GAG GGA AAC CGA ATG AGG AAA AAG AGT TTT TGG.  
TiK117: 5' CGC GGT CGG GTA CCG TTT GCG CCA AGG CAT G.

## SUBT\_BACAM P00782

TiK112: 5' GAG GAG GGA AAC CGA ATG AGA GGC AAA AAA GTA TGG.  
15 TiK118: 5' CGC GGT CGG GTA CCG ACT GCG CGT ACG CAT G.

## D26542

TiK110: 5' GAG GAG GGA AAC CGA ATG AGA CAA AGT CTA AAA GTT ATG.  
TiK116: 5' CGC GGT CGG GTA CCG TTT GAC TGA TGG TTA CTT C.

20

## A22550

TiK109: 5' GAG GAG GGA AAC CGA ATG AAG AAA CCG TTG GGG.  
TiK115: 5' CGC GGT CGG GTA CCG ATT GCG CCA TTG TCG TTA C.

25 PD498

TiK113: 5' GAG GAG GGA AAC CGA ATG AAG TTC AAA AAA ATA GCC.  
TiK119: 5' CGC GGT CGG GTA CCG CAG AAT AGT AAG GGT CAT TC.

The obtained DNA fragments of a length between 300-400 bp were purified by agarose gel-electrophoresis with subsequent gel extraction (QIAGEN) and subjected to assembly by splice-by-overlap extension PCR (SOE-PCR).

## 2) SOE-PCR

35 The pre-pro fragments were then separately spliced by SOE-PCR to the 3' part of the promoter of the vector pKH400. The 3' part of the promoter was obtained by standard PCR with the Pwo DNA polymerase using 1 ng of pKH400 as template and the primers:

TiK106: 5' CGA CGG CCA GCA TTG G.

TiK107: 5' CAT TCG GTT TCC CTC CTC.

The resulting 160 bp fragment was gel-purified. Subsequently, 5 SOE-PCRs were performed under standard conditions (Pwo DNA polymerase) using as template each of the 5 pre-pro sequences mixed with equal molar amounts of the 3' part of the promoter. The assembling primers were:

TiK120: 5' CTT TGA TAC GTT TAA ACT ACC.

TiK121: 5' CGC GGT CGG GTA CCG.

10 The obtained fragments were also gel-purified.

3) Insertion of the pre-pro sequences into the pKH400 shuttle vector

The pKH400 vector was cut with Pme I and Acc65 I to remove 15 the existing linker sequence. The 5 purified SOE-PCR fragments from 2) were also digested with the same enzymes and gel-purified. Only with the SOE-PCR of the SUBT\_BACAM P00782 pre-pro sequence special caution was required because it contains an internal Pme I-site so that a partial digest was performed. In separate stan- 20 dard ligation mixes the pre-pro fragments were then ligated to the pKH400 vector. After transformation of DH10B E.coli cells, colonies were selected on ampicillin containing media. Correctly transformed cells were identified by control digest and sequenced. The thus obtained vectors were named pTK4001-4005.

25

B)Preparation of the small fragments of the protéases A13050\_1 (GenBank), SUBT\_BACAM P00782 (Swiss-Prot), D26542 (GenBank), A22550 (GenBank), and PD498 (Patent Application No. WO 96/34963).

30 1) Standard PCR reactions were assembled with 0.5 µl of mini-prep DNA of each protease gene as templates. Since these five protease genes shall be fragmented into six fragments (I-VI), 30 PCRs are required (see fig 1). The Ampli-Tag polymerase (5U) was used in combination with the following primer sets (the numbering corre- 35 sponds to the amino acid position in A22550). If there are primers labeled #.1, #.2, etc., then equal molar amounts of them are mixed prior to PCR and treated as one primer in the PCR:

## Set I)

TiK122.1 (116-124)

5' CCG GCG CAG GCG GTA CCX TRS GGX ATW XCX CXX RTX MAA GC.

TiK122.2 (116-124)

5 5' CCG GCG CAG GCG GTA CCX TRS GGX ATW XCA WWC ATX WAT AC.

TiK123 (174-180)

5' GTT CCX GCX ACR TGX GTX CC.

## Set II)

10 TiK124 (174-180)

5' GGX ACX CAY GTX GCX GGA AC.

TiK125.1 (217-223)

5' GCC CAC TSX AKX CCG YTX AC.

TiK125.2 (217-223)

15 5' GCC CAC TSX AKX CCT YGX GC.

TiK125.3 (217-223)

5' GCC CAX TSR AKX CCK XXX RCW AT.

## Set III)

20 TiK126.1 (217-223)

5' GTX ARC GGX MTX SAG TGG GC.

TiK126.2 (217-223)

5' GCX CRA GGX MTX SAG TGG GC.

TiK126.3 (217-223)

25 5' TWG CYC AAG GWW TXS AMT GHR.

TiK126.5 (217-223)

5' TWG CTC AAG GHH THS ART GG.

TiK127.1 (255-261)

5' GCX GCX ACX ACX ASX ACX CC.

30 TiK127.2 (255-261)

5' GCY SCW AYW AMX AGW AYA YCA.

## Set IV)

TiK128.1 (255-261)

35 5' GGX GTX STX GTX GTX GCX GC.

TiK128.2 (255-261)

5' TGR TRT WCT MKT WRT WGS RGC.

TiK129.1 (292-299)

5' GBX CCX ACR YTX GAR AAW GAX G.

TiK129.2 (292-299)

5' GBX CCR TAC TGX GAR AAR CTX G.

TiK129.3 (292-299)

5 5' GKX CCA TAC KKA GAR AAR YTT G.

TiK129.5 (292-299)

5' GKR CCA TAC KKA GAR AAG YTT G.

Set V)

10 TiK130.1 (292-299)

5' CXT CWT TYT CXA RYG TXG GXV C.

TiK130.2 (292-299)

5' CXA GYT TYT CXC AGT AYG GXV C.

TiK130.3 (292-299)

15 5' CAA GYT TCT CTM MGT ATG GSM C.

TiK130.5 (292-299)

5' CAA GTT TCT CTC AGT ATG GGA C.

TiK131.1 (324-330)

5' GGX GWX GCC ATX GAY GTX CC.

20 TiK131.2 (324-330)

5' GGA GTA GCC ATX GAX GTW CC.

Set VI)

TiK132.1 (324-330)

25 5' GGX ACR TCX ATG GCX WCX CC.

TiK132.2 (324-330)

5' GGW ACX TCX ATG GCA WCX CC.

TiK133.1 (375-380)

5' CGG CCC CGA CGC GTT TAC YGX RYX GCX SYY TSX RC.

30 TiK133.2 (375-380)

5' CGG CCC CGA CGC GTT TAT CKT RYX GCX XXY TYW G.

TiK133.3 (375-380)

5' CGG CCC CGA CGC GTT TAT CKT RCX GCX GCX TYT GMR TT.

TiK133.4 (375-380)

35 5' CGG CCC CGA CGC GTT TAT CTT ACG GCA GCC TCA GC.

(X = deoxy-inosine, Y = 50% C + 50% T, R = 50% A + 50% G, S = 50% C + 50% G, W = 50% A + 50% T, K = 50% T + 50% G, M = 50% A + 50%

C, B = 33.3% C + 33.3% G + 33.3% T, V = 33.3% C + 33.3% G + 33.3% A, H = 33.3% C + 33.3% A + 33.3%).

After 30 cycles at annealing temperatures ranging from 40-5 60°C the amplified fragments were gel-purified and recovered.

2) SOE-PCR to randomly assemble the small fragments

Equimolar amounts of each of the purified fragments were taken and mixed in one tube as templates for assembly in an other-10 wise standard SOE-PCR with Ampli-Taq polymerase. The external primers used are:

TiK134.1: CCG GCG CAG GCG GTA CC.

TiK135.1: CGG CCC CGA CGC GTT TA.

15 Also the primer pairs

TiK134.2: GGC GCA GGC GGT AC.

TiK135.2: GCC CCG ACG CGT TTA.

and

TiK134.3: CGC AGG CGG TAC.

20 TiK135.3: CCC GAC GCG TT.

can be used. The annealing temperatures are ranging from 40°C to 70°C.

The re-assembly is also achieved by sequentially re-25 assembling all conceivable combinations of fragments, e.g.: In tube 1 all seven fragments obtained by PCR with the primers of set I (see above, B1-2) are mixed, in tube 2 fragments obtained by PCR with the primers of set II are mixed, in tube 3 fragments obtained by PCR with the primers of set III are mixed, in tube 4 fragments obtained by PCR with the primers of set IV are mixed, in tube 5 30 fragments obtained by PCR with the primers of set V are mixed, in tube 6 fragments obtained by PCR with the primers of set VI are mixed.

Then, a SOE-PCR is performed by mixing aliquots of tube 1 and 2 and using the resulting mixture as template for a primary 35 SOE-PCR with corresponding external primers. The same is performed with mixtures of aliquots of tubes 3 and 4 as well as tubes 5 and 6. The respective external primer pairs are TiK134.#/125.# for fragments 1 and 2, TiK126.#/129.# for fragments 3 and 4, and TiK



130.#/135.# for fragments 5 and 6. The amplified assembled fragments of about 340, 260, and 280 bp length, respectively, are purified by agarose gel electrophoresis. In a secondary SOE-PCR the obtained fragments are mixed and assembled using primer pair 5 TiK134.#/135.# as external primers. The obtained full-length protease genes are gel-purified as described above.

In another example, aliquots of tubes 1, 2, and 3 are mixed and re-assembled by a primary SOE-PCR with primer pair TiK134.#/127.#. Aliquots of tubes 4, 5, and 6 are also mixed in 10 another tube and re-assembled by another SOE-PCR using the primers TiK128.#/135.#. The generated fragments of about 450 bp length are purified as described above, mixed and reassembled in a secondary SOE-PCR with external primers TiK134.#/135.#. The obtained full-length protease genes are gel-purified as described above.

15 In principle, every combination of fragments may be assembled in separate SOE-PCRs. In subsequent SOE-PCRs the obtained assembled units are assembled to larger units until the final full length gene is obtained. The overall number of SOE-PCRs used for that purpose is only limited by experimental capacity. The only 20 prerequisite which is inherent to SOE-PCR is that the fragments to be assembled must contain a sequence overlap as defined earlier.

C) Cloning of the SOE-PCR-derived full-length protease-hybrids to yield library #1

25 The full-length protease-hybrid genes from step B2) as well as the newly constructed shuttle vectors pTK4001-4005 from A3) are separately digested with Acc65 I and Mlu I. In standard ligation procedures the protease genes are separately ligated to each of the five vectors pTK4001-4005 and transformed into E.coli DH103. 30 Selection of correctly transformed cells is performed with ampicillin. DNA of these clones is prepared and designated library #1. The library size is about  $10^5$  independent transformants.

D) Screening of library #1

35 Aliquots of library #1 are used to transform Bacilli cells DN1885. The transformants are screened for the desired properties.

By this method and using a standard protease activity assay to screen for the desired property in step D) above a number of new shuffled subtilisins with a desired property were identified.

The results are indicated in Table 1 below.

5

Table 1

Clone	pre-pro	frag.1 (5')	frag.2	frag.3	frag.4	frag.5	frag.6 (3')
8	BPN	Sav	Sav	Sav	Sav	Sav	Sav
6	Alc	Sav	Sav	Sav	Sav	Sav	Sav
12	Esp	Sav	Sav	Sav	Sav	Sav	Sav
10	PD498	Sav	Sav	Sav	Sav	Sav	Sav
4	Esp	PD138	Esp	Esp	Esp	Esp	JA16
22	Alc	PD138	Esp	Esp	Esp	Esp	JA16
11	PD498	PD138	Esp	Esp	Esp	Esp	JA16
1	Alc	PD138	Esp	PD138	Esp	Esp	JA16
3	BPN	PD138	Esp	Esp	PD138	Sav	Sav
17	Esp	PD138	PD138	Esp	Esp	Esp	JA16
19	PD498	Alc	BPN	Esp	Esp	Esp	JA16
16	Alc	Alc	BPN	Esp	PD138	Esp	JA16

Identity of clones:

- 10 Alcalase: A13050\_1 (GenBank)      BPN: Poo782 (SwisProt)  
 Esperase: D26542 (GenBank)      Savinase: A22550 (GenBank)  
 PD498: WO 96/34963      JA16: WO 92/17576  
 PD138 WO 93/18140

15      23 clones having protease activity were identified of which 12 were different. Clones 8, 9, 18, 20, 23 were the same; clones 6, 15, 21 were the same, clones 12, 14 were the same, clones 10, 13 were the same, and clones 4, 7 were the same. In respect of mature enzymes 7 different were identified.

20      From Table 1 it is seen that the process of the invention makes it possible to obtain active proteins representing combinations of proteins quite distantly related.

## 25 Example 2

The same methods as described in example 1 can be used for amplification of PCR fragments from fungal lipases.

The fungal lipases from the following fungi are aligned using the alignment program from Geneworks (using the following pa-

rameters: cost to open a gap = 5, cost to lengthen a gap = 25, Minimum Diagonal lLength = 4, Maximum Diagonal Length = 10, Consensus cutoff = 50%): Rhizomucor Miehei (LIP\_RHIMI from the Swiss Prot data base), Rhizopus Delemar (LIP\_RHIDL from the Swiss Prot data base), Penecillium camenbertii (MDLA\_PENCA from the Swiss Prot data base) Absidia reflexa (WO 96/13578) and Humicola lanuginosa (US 5536661).

Primers for amplification of Absidia (Absidia), Rhizopus (LIP\_RHIDL) and Rhizomucor (LIP\_RHIMI) lipase genes for shuffling  
 10 N: according to the IUPAC nomenclature means all 4 bases (A,T,G,C).

Set 1)

5' primer for YCRT/SVI/VPG: TAY TGY MGR ACN GTN ATH CCN GG or  
 15 TAY TGY MGR AGY/TCN GTN GTN CCN GG  
 3' primer for VFRGT/S: NSW NCC YCK RAA NAC

Set 2)

5' primer for VFRGT/S: GTN TTY MGR GGN WSN  
 20 3' primer for KVHK/AGF: RAA NCC YTT RTG NAC YTT or  
 RAA NCC NGC RTG NAC YTT

Set 3)

5' primer for KVHK/AGF: AAR GTN CAY AAR GGN TTY or  
 25 AAR GTN CAY GGN GGN TTY  
 3' primer for VTGHS LGG: CC NCC YAR NGA RTG NCC NGT NAC or  
 CC NCC YAR RCT RTG NCC NGT NAC

Set 4)

30 5' primer for VTGHS LGG: GTN ACN GGN CAY TCN YTR GGN GG or  
 GTN ACN GGN CAY AGY YTR GGN GG  
 3' primer for FGFLH: RTG YAR RAA NCC RAA

Set 5)

35 5' primer for FGFLH: TTY GGN TTY YTR CAY  
 3' primer for IVPFT: NGT RAA NGG NAC DAT

Primers for amplification of *Humicola lanuginosa* (*Humicola*) and *Penicillium camembertii* (MDLA\_PENCA) lipase genes for shuffling

## Set 1)

- 5 5' primer for CPEVE: TGY CCN GAR GTN GAR  
 3' primer for VLS/AFRG: NCC LCK RAA NGM YAR NAC

## Set 2)

- 5' primer for VLS/AFRG: GTN YTR KCN TTY MGR GGN  
 10 3' primer for GFT/WSSW: CCA NGA NGA NGT RAA NCC or  
 CCA RSW RSW CCA RAA NCC

## Set 3)

- 5' primer for GFT/WSSW: GGN TTY ACN TCN TCN TGG or  
 15 GGN TTY TGG WSY WSY TGG  
 3' primer for GHSLGG/AA: NGC NSC NCC YAR NGA RTG NCC or  
 NGC NSC NCC YAR RCT RTG NCC

## Set 4)

- 20 5' primer for GHSLGG/AA: GGN CAY TCN YTR GGN GSN GCN or  
 GGN CAY AGY YTR GGN GSN GCN  
 3' primer for PRVGN: RTT NCC NAC YCK NGG

## Set 5)

- 25 5' primer for PRVGN: CCN MGR GTN GGN AAY  
 3' primer for THTND: RTC RTT NGT RTG NGT

## Set 6)

- 5' primer for THTND: ACN CAY ACN AAY GAY  
 30 3' primer for PEYWI: DAT CCA RTA YTC NGG

## Set 7)

- 5' primer for PEYWI: CCN GAR TAY TGG ATH  
 35 3' primer for AHL/IWYF: RAA RTA CCA DAK RTG NGC

Primers for shuffling of all five genes:

## Set 1)

5' primer for AN/TA/SYCR: GCN AMY KCN TAY TGY MG for Absidia, Rhizopus and Rhizomucor sequences

5' primer for AN/TA/SYCGKNDA: GCN AMY KCN TAY TGY GGN AAR AAY AAY  
5 GAY GC for Humicola

5' primer for AN/TA/SYCEADYTA: GCN AMY KCN TAY TGY GAR GCN GAY TAY  
ACN GC for P. camembertii

3' primer for E/OKTIY: RTA DAT NGT YTT YTS for Absidia, Rhizopus  
10 and Rhizomucor sequences

3' primer for ALDNTE/OKTIY: RTA DAT NGT YTT YTS NGT RTT RTC YAR  
NGC for Humicola

3' primer for AVDHTE/OKTIY: RTA DAT NGT YTT YTS NGT RTG RTC NAC  
NGC for P. camembertii

15

## Set 2)

5' primer for E/OKTIY: SAR AAR ACN ATH TAY for Absidia, Rhizopus  
and Rhizomucor sequences

5' primer for E/OKTIYLA/SFRG: SAR AAR ACN ATH TAY YTR KCN TTY MGR  
20 GGN for the two other sequences

3' primer for KVHK/AGF: RAA NCC YTT RTG NAC YTT or RAA NCC NGC RTG  
NAC YTT for Absidia, Rhizopus and Rhizomucor sequences

3' primer for ICSGCKVHK/AGF: RAA NCC YTT RTG NAC YTT RCA NCC NGA  
25 RCA DAT or RAA NCC NGC RTG NAC YTT RCA NCC NGA RCA DAT for Humi-  
cola

3' primer for LCDGCKVHK/AGF: RAA NCC YTT RTG NAC YTT RCA NCC RTC  
RCA YAR or RAA NCC NGC RTG NAC YTT RCA NCC RTC RCA YAR for P. ca-  
menbertii

30

## Set 3)

5' primer for KVHK/AGF: AAR GTN CAY AAR GGN TTY or AAR GTN CAY GCN  
GGN TTY for Absidia, Rhizopus and Rhizomucor sequences

5' primer for KVHK/AGFTSSW: AAR GTN CAY AAR GGN TTY ACN TCN TCN  
35 TGG or AAR GTN CAY GCN GGN TTY ACN TCN TCN TGG for Humicola

5' primer for KVHK/AGFWSSW: AAR GTN CAY AAR GGN TTY TGG WSY WSY  
TGG or AAR GTN CAY GCN GGN TTY TGG WSY WSY TGG for P. camembertii

3' primer for GHSLGG/AA: NGC NSC NCC YAR NGA RTG NCC or NGC NSC  
NCC YAR RCT RTG NCC for all five sequences

Set 4)

5 5' primer for GHSLGG/AA: GGN CAY TCN YTN GGN GSN GCN or GGN CAY  
AGY YTN GGN GSN GCN for all five sequences

3' primer for PRVGN/D: RTY NCC NAC YCK NGG for all the genes ex-  
cept Absidia

10 3' primer for TQGQPRVGN/D: RTY NCC NAC YCK NGG YTG NCC YTG NGT for  
Absidia

Set 5)

5' primer for PRVGN/D: CCN MGR GTN GGN RAY for all the genes ex-  
15 cept Absidia

5' primer for PRVGN/DPAPA: CCN MGR GTN GGN RAY CCN GCN TTY GCN for  
Absidia

3' primer for RDIVPH/R/K: YK NGG NAC DAT RTC YCK for Absidia,  
20 Rhizopus and Rhizomucor sequences

3' primer for I/FTHTRDIVPH/R/K: YK NGG NAC DAT RTC YCK NGT RTG NGT  
RAW for the two other sequences

Set 6)

25 5' primer for RDIVPH/R/K: MGR GAY ATH GTN CCN MR for Absidia,  
Rhizopus and Rhizomucor sequences

5' primer for RDIVPH/R/KLP: MGR GAY ATH GTN CCN MRN YTR CCN for  
the two other sequences

30 3' primer for EYWIK/T: YKT DAT CCA RTA YTC for Rhizomucor, Humi-  
cola and P.camenbertii

3' primer for PGVEYWIK/T: YKT DAT CCA RTA YTC NAC NCC NGG for  
Rhizopus

3' primer for AGEEYWIK/T: YKT DAT CCA RTA YTC YTC NCC NGC for Ab-  
35 sidia

Set 7)

5' primer for EYWIK/T: GAR TAY TGG ATH AAR or GAR TAY TGG ATH ACN  
for Rhizomucor, Humicola and P.camenbertii

5' primer for EYWIKSGT: GAR TAY TGG ATH AAR WSY GGN ACN for  
5 Rhizopus

5' primer for EYWIKKDSS: GAR TAY TGG ATH AAR AAR GAY WSY WSY for  
Absidia

3' primer for DHLSY: RTA NGA/RCT YAR RTG RTC for Absidia, Rhizopus  
10 and Rhizomucor sequences

3' primer for IPDIPDHLSY: RTA NGA/RCT YAR RTG RTC NGG DAT RTC NGG  
DAT for Humicola

3' primer for TDFEDHLSY: RTA NGA/RCT YAR RTG RTC YTC RAA RTC NGT  
for P.camenbertii

15

For the SOE-PCR the 5' primers from the first set of primers  
and the 3' primer for the last set of primers can be used.

The SOE-PCR fragments can then be combined with a lipase 5'  
and 3' end, when the 5' and 3' ends have been generated by PCR.  
20 The 5' end can be generated by PCR by using specific 5' primers  
(containing a sequence for the BamHI recognition site in the 5'  
end) for the 5' end of the genes of interest and using the comple-  
mentary sequence from the 5' primer from the first set of primers  
as the 3' primer. The 3' end can be generated by PCR by using spe-  
25 cific 3' primers (containing a sequence for the XbaI recognition  
site in the 5' end) for the 3' end of the genes of interest and  
the complementary sequence from the 3' primer from the last set of  
primers as the 5' primer.

A second SOE is then used to generate the complete sequence,  
30 by using the specific 5' and 3' primers from the genes of inter-  
est.

The genes can then be cloned into the yeast vector pJSO26 as  
a BamHI-XbaI fragment (see WO 97/07205).

### Example 3

The overall same method as described in example 2 can be  
used for amplification and recombination of PCR fragments of  
Pseudomonas lipases. The term "overall same method" denotes that

it may be advantageous to use slightly different vectors as compared to example 2. Based on the sequence and primer information disclosed below it is a matter of routine for a person skilled in the art to modify the vectors etc. from example 2, in order to recombine below mentioned *Pseudomonas* lipases according to a shuffling method of the invention.

The *Pseudomonas* lipases mentioned below are aligned using the alignment program from Geneworks (using the following parameters: cost to open a gap = 5, cost to lengthen a gap = 25, Minimum Diagonal Length = 4, Maximum Diagonal Length = 10, Consensus cutoff = 50%).

*Pseudomonas* lipases

*Pseudomonas aeruginosa* TE3285 (file ate3285d)

*Pseudomonas pseudoalcaligenes* M1 (Lipomax wt) (file pseudm1d)

*Pseudomonas* sp. SD705 (mature)(file spsd705d)

*Pseudomonas wisconsinensis* (file wisconsd) *Proteus vulgaris* K50 (file provulgd) *Pseudomonas fragi* IFO 12049 (file fr12049d).

Suitable primers for shuffling of *Pseudomonas* lipases:

I = Inosin, Numbers refer to the numbers in the alignment(see figure 4), S means sense strand, the antisense oligonucleotide is of course also used:

- 5 109-131  
S1: 5'-TA(C/T)CCIAT(C/T)(G/T)I(C/T)T(G/A)(G/A)(C/T)ICA(C/T)GG-3'
- 250-269  
S2: 5'-GA(G/A)(G/C)IICGIGGIG(A/C)I(G/C)A(G/A)(T/C)T-3'
- 10 318-343  
S3: 5'-GT(C/A)AA(C/T)(C/T)T(G/A)ITCGG(C/T)CA(C/T)AG(C/T)CAIGG-3'
- 607-626  
15 S4: 5'-  
TIAA(C/T)(G/C/A)(G/C/A)(C/T/A)(A/C)(A/G)I(T/C)(A/T)(C/T)CCI(C/T)(A/G)(T/G/A)GG-3'
- 801-817  
20 S5: 5'-AA(C/T)GA(C/T)GG(C/T)(C/A/T)TGGT(C/T/G)GG-3'
- 871-890  
S6: 5'-  
CA(C/T)(C/G)T(C/G)GA(C/T)(G/A)(A/C/T)(G/C)(G/A)T(G/C/A)AACCA-3'



## CLAIMS

1. A method for shuffling of heterologous sequences of interest comprising the following steps,
- 5           i) identification of at least one conserved region between the heterologous sequences of interest;
- ii) generating fragments of each of the heterologous sequences of interest, wherein said fragments comprise the conserved region(s); and
- 10          iii) shuffling/recombining said fragments using the conserved region(s) as (a) homologous linking point(s).
2. A method for producing a shuffled protein having a desired biological activity comprising in addition to the steps of the claim
- 15 1 the following further steps:
- iv) expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences from step iii) (in claim 1); and
- v) screen or select the numerous different recombinant
- 20          proteins from step ii) in a suitable screening or selection system for one or more recombinant protein(s) having a desired activity.
3. The method for shuffling of heterologous DNA sequences of
- 25 interest, according to claim 1, having at least one conserved region comprising the following steps
- i) identification of one or more conserved region(s) (hereafter named "A,B,C" etc..) in two or more of the heterologous sequences;
- 30          ii) construction of at least two sets of PCR primers (each set comprising a sense and an anti-sense primer) for one or more conserved region(s) identified in i) wherein
- in one set the sense primer (named: "a"=sense primer) is directed to a sequence region 5' (sense strand) of said
- 35          conserved region (e.g. conserved region "A"), and the anti-sense primer (named "a'"=anti-sense primer) is directed either to a sequence region 3' (sense strand) of said

- conserved region or directed to a sequence region at least partially within said conserved region,  
and in the second set the sense primer (named: "b"=sense primer) is directed either to a sequence region 5' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region and the anti-sense primer (named: "b'"=anti-sense primer) is directed to a sequence region 3' (sense strand) of said conserved region (e.g. conserved region "A"), and  
the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions including the actual primer sequences) have a homologous sequence overlap of at least 10 base pairs (bp) within the conserved region;
- iii) for one or more identified conserved region of interest in step i) two PCR amplification reactions are performed with the heterologous DNA sequences in step i) as template, and where  
one of the PCR reactions is using the 5' primer set identified in step ii) (e.g. named "a","a'") and the second PCR reaction is using the 3' primer set identified in step ii) (e.g. named "b","b'");
- iv) isolation of the PCR fragments generated as described in step iii) for one or more of the identified conserved region in step i);
- v) pooling of two or more isolated PCR fragments from step iv) and performance of a Sequence overlap extension PCR reaction (SOE-PCR) using said isolated PCR fragments as templates; and
- vi) isolation of the PCR fragment obtained in step v), wherein said isolated PCR fragment comprises numerous different shuffled sequences containing a shuffled mixture of the PCR fragments isolated in step iv), wherein said shuffled sequences are  
characterized in that the partial DNA sequences, originating from the homologous sequence overlaps in step ii), have at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

4. The method for producing one or more recombinant protein(s) having a desired biological activity, according to claim 2, comprising:
- 5 shuffling of heterologous DNA sequences, having at least one conserved region, encoding a protein by
- i) identification of one or more conserved region(s) (hereafter named "A,B,C" etc..) in two or more of the heterologous sequences;
  - 10 ii) construction of at least two sets of PCR primers (each set comprising a sense and an anti-sense primer) for one or more conserved region(s) identified in i) wherein  
in one set the sense primer (named: "a"=sense primer) is directed to a sequence region 5' (sense strand) of said  
15 conserved region (e.g. conserved region "A"), and the anti-sense primer (named "a'"=anti-sense primer) is directed either to a sequence region 3' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region,  
20 and in the second set the sense primer (named: "b"=sense primer) is directed either to a sequence region 5' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region and the anti-sense primer (named: "b'"=anti-sense primer) is  
25 directed to a sequence region 3' (sense strand) of said conserved region (e.g. conserved region "A"), and the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions is including the actual primer sequences) have a homologous  
30 sequence overlap of at least 10 base pairs (bp) within the conserved region;
  - iii) for one or more identified conserved region of interest in step i) two PCR amplification reactions are performed with the heterologous DNA sequences in step i) as template, and  
35 where  
one of the PCR reactions is using the 5' primer set identified in step ii) (e.g. named "a","a'") and the second

- PCR reaction is using the 3' primer set identified in step ii) (e.g. named "b", "b'");
- iv) isolation of the PCR fragments generated as described in step iii) for one or more of the identified conserved region in step i);
- 5 v) pooling of two or more isolated PCR fragments from step iv) and performance of a Sequence overlap extension PCR reaction (SOE-PCR) using said isolated PCR fragments as templates; and
- 10 vi) isolation of the PCR fragment obtained in step v), wherein said isolated PCR fragment, comprises numerous different shuffled sequences containing a shuffled mixture of the PCR fragments isolated in step iv), wherein said shuffled sequences are
- 15 characterized in that the partial DNA sequences, originating from the homologous sequence overlaps in step ii), have at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i);
- 20 vii) expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences in step vi); and
- viii) screen or select the numerous different recombinant proteins from step vii) in a suitable screening or selection system
- 25 for one or more recombinant protein(s) having a desired activity.
5. The method according to any of claims 1-4, wherein the heterologous sequences of interest are encoding an enzyme.
- 30
6. The method according to claim 5, wherein the enzyme is a protease, preferably a serine protease, and in particular a subtilase; or a lipase.
- 35 7. The method according to any of claims 3 and 4, wherein the PCR amplification process in step iii) is performed under conditions resulting in a low, medium or high random mutagenesis frequency.

8. The method according to any of claims 2 and 4, wherein the desired activity is an activity which leads to performance of the recombinant protein(s) in a dish-wash or laundry detergent.




Fig. 1

1 M M R - K K S F W L G M L T A E M L V F T M A F S D S A S A A13050\_1.PRO  
1 M - K - K P L G K I V A S T A L L I S - - V A F S S S I A S A22550.PRO  
1 M - R - Q S L K V M V L S T - - - V A - - L L F M A N P A A D26542.PRO  
1 M - R - G K K V W I S L L F A L A I I F T M A F G S T S S A P00782.PRO  
1 M - K F K K I A A L S L A T S L A L F - - P A F G G S S L A P0493.PRO

30 A Q P - - - - - A K - N V E K - - - - - D - Y I V G F A13050\_1.PRO  
27 A A E - - - - - E A - - - K - - - - - E K Y L I - - A22550.PRO  
24 A S E - - - - - E K - - - K - - - - - E - Y L I - - D26542.PRO  
29 Q A A - - - - - G K S N G E K - - - - - K - Y I V G F P00782.PRO  
28 K E A P K P F Q P I N K - T L D K G A F E S G E - V I V K E P0493.PRO

45 K S G - - - - - - - - - - - V K - - T - - A S V K K D A13050\_1.PRO  
38 - - - G F N E Q E A V S E F V E Q V E - - A N D E V A I L S A22550.PRO  
34 - - - - - - - - - - - V V - - E P E E V S A Q S D26542.PRO  
45 K Q T - - - - - - - - - - - M S - - T M S A A K K K D P00782.PRO  
56 K D G - - - - - - - - - - - V S K K A Q G S A L N K A P0493.PRO

57 I I K E S G G K V O K Q F R I I N A A K A K L O K E A L K E A13050\_1.PRO  
63 E E E E V E I E L L R E F E T I P V L S V E L S P E D V O A A22550.PRO  
45 V E E S Y D V D V I H E F E E I P V I H A E L T K K E L K K D26542.PRO  
59 V I S E K G G K V Q K Q F K Y V D A A S A T L N E K A V K E P00782.PRO  
72 E A N E Q K A S A K D P E Q V L E V A D V - - - O Q A V K A P0493.PRO

87 V K N D P D V A Y V E E D - - - - - H V A H A L A Q T V A13050\_1.PRO  
93 L E L D P A I S Y I E E D - - - - - A E V T T M A Q S V A22550.PRO  
75 L K K D P N V K A I E E N - - - - - A E V T - I S Q T V D26542.PRO  
89 L K K O P S V A Y V E E D - - - - - H V A H A Y A Q S V P00782.PRO  
99 L E M N P N V E Y A E P N Y T F Q A T H S P N O P Y Y S A Y P0493.PRO

110 P Y G I P L I K A D K V Q A Q G F K G A N V K V A V L O T G A13050\_1.PRO  
115 P W G I S R V Q A P A A H N R G L T G S G V K V A V L O T G A22550.PRO  
97 P W G I S F I N T Q Q A H N R G I F G N G A R V A V L O T G D26542.PRO  
112 P Y G V S Q I K A P A L H S Q G Y T G S N V K V A V I D S G P00782.PRO  
129 Q Y G P Q N T S T P A A W D V T R G S S T Q T V A V L D S G P0493.PRO

140 I Q A S H P D L - - N V V G G A S F V A G E A Y N - T O G N A13050\_1.PRO  
146 I - S T H P D L - - H I R G G A S F V P G E P S T - Q D G N A22550.PRO  
127 I - A S H P D L - - R I A G G A S F I S S E P S Y - H O N N D26542.PRO  
142 I D S S H P D L - - K V A G G A S M V P S E T N P F Q O N N P00782.PRO  
159 V O Y N H P D L A R K V I K G Y D E I D R O N N P - M O L N P0493.PRO

157 G H G T H V A G T V A A - L O N T T G V L G V A P S V S L Y A13050\_1.PRO  
172 G H G T H V A G T I A A - L N N S I G V L G V A P S A E L Y A22550.PRO  
153 G H G T H V A G T I A A - L N N S I G V L G V A P S A D L Y D26542.PRO  
170 S H G T H V A G T V A A - L N N S I G V L G V A P S A S L Y P00782.PRO  
188 G H G T H V A G T V A A D T N N G I G V A G M A P O T K I L P0493.PRO

196 A V K V L N S S G S G S Y S G I V S G I E W A T T N G M D V A13050\_1.PRO  
201 A V K V L G A S G S G S V S S I A Q G L E W A G N N G M H V A22550.PRO  
192 A V K V L D R N G S G S L A S V A Q G I E W A I N N N M H I D26542.PRO  
199 A V K V L G A D G S G Q Y S W I I N G I E W A I A N N M D V P00782.PRO  
212 A V R V L D A N G S G S L D S I A S G I R Y A A D Q G A K V P0493.PRO

Fig. 2 (a)

SUBSTITUTE SHEET (RULE 26)

226	I N M S L G G A S G S T A M K Q A V D N A Y A R G V V V V A	A13050_1.PRO
231	A N L S L G S P S P S A T L E Q A V N S A T S R G V L V V A	A22550.PRO
212	I N M S L G S T S G S S T L E L A V N R A N N A G I L L V G	D26542.PRO
229	I N M S L G G P S G S A A L K A A V D K A V A S G V V V V A	P00732.PRO
248	L N L S L G C E C N S T T L K S A V D Y A W N K G A V V V A	P0493.PRO
256	A A G N S G S S G N T N T I G Y P A K Y D S V I A V G A V D	A13050_1.PRO
261	A S G N S G A G S I S - - - - Y P A R Y A N A M A V G A T D	A22550.PRO
242	A A G N T G R Q G V N - - - - Y P A R Y S G V M A V A A V D	D26542.PRO
259	A A G N E G T S G S S S T V G Y P G K Y P S V I A V G A V D	P00732.PRO
278	A A G N D N V S R T F - - - - Q P A S Y P N A I A V G A I D	P0493.PRO
296	S N S W R A S F S S V G A E L E V M A P G A G V Y S T Y P T	A13050_1.PRO
297	Q N N N R A S F S Q Y G A G L D I V A P G V N V Q S T Y P G	A22550.PRO
268	Q N G Q R A S F S T Y G P E I E I S A P G V N V N S T Y T G	D26542.PRO
289	S S M Q R A S F S S V G P E L D V M A P G V S I Q S T L P G	P00732.PRO
304	S N D R K A S F S N Y G T W V O V T A P G V N I A S T V P N	P0493.PRO
316	N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N L	A13050_1.PRO
317	S T Y A S L N G T S M A T P H V A G A A A L V K Q K N P S W	A22550.PRO
298	N R Y V S L S G T S M A T P H V A G V A A L V K S R Y P S Y	D26542.PRO
319	N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N W	P00732.PRO
334	N G Y S Y M S G T S M A S P H V A G L A A L L A S Q - - G K	P0493.PRO
346	S A S Q V R N R L S S T A T Y L - - - G S S F Y Y G K G L I	A13050_1.PRO
347	S N V Q I R M H L K N T A T S L - - - G S T N L Y G S G L V	A22550.PRO
328	T N N Q I R Q R I N Q T A T Y L - - - G S P S L Y G N G L V	D26542.PRO
349	T N T Q V R S S L E N T T K L - - - G D S F Y Y G K G L I	P00732.PRO
362	N N V Q I R Q A I E Q T A D M I S G T G T N F K Y G K - - I	P0493.PRO
373	N V E A A A Q	A13050_1.PRO
374	N A E A A T R	A22550.PRO
355	H A G R A T Q	D26542.PRO
375	N V Q A A A Q	P00732.PRO
390	N S N K A V R Y	P0493.PRO

Fig. 2 (b)



Percent Similarity

	1	2	3	4	5		
1	██████	52.2	48.6	66.5	41.8	1	A13050_1.PRO
2	74.2	██████	59.9	51.6	41.8	2	A22550.PRO
3	83.6	56.7	██████	48.1	39.4	3	D26542.PRO
4	44.2	75.6	85.2	██████	45.4	4	P00782.PRO
5	100.0	100.0	100.0	93.1	██████	5	PD498.PRO
	1	2	3	4	5		

Fig. 2 (c)

LIP_RHIMI	MV-LKQRANY	LGF-LIVFFT	AFLVEAVPI-	-KQSNSTV-	-----	DSLPP	40
LIP_RHIDL	MVSFISISQG	VSLCLLVSSH	MLGSSAVPVS	GRSGSSNTAV	SASDNAALPP		50
ABSIDIA	M-----	HSHF	VVLLAVFIC	MCSVSGVPL-	-QIDPRDDK-	-----	SYVPE
MDLA_PENCA	M-----	R	LSFFTALSA-	---VASLG--	-----	YA-LPG	21
Humicola	M-----	R	SSL--VLFF-	---VSAWT--	-----	A-LAS	18
Consensus	M-----	....	.SL.L.VF..	...VSAVP.-	-----	A.LP.	50
.							
LIP_RHIMI	LIPSRTSAPS	SSPSTTPEA	-P-AM-----	---SRNGPLP	S--DVETKY-		77
LIP_RHIDL	LISSRCAPPS	NKGSKSDLQA	EPYMQKQKTE	WYESHGGNLT	SIGKRDDNLV		100
ABSIDIA	QYPLKVNQPL	PEGVSVIQGY	-----	---CENCTMY	P----EKN--		68
MDLA_PENCA	KLQSR-----	-----	-----	-----	-----	D----	27
Humicola	PIR-R-----	-----	-----	-----	-----	E----	23
Consensus	.I.SR...P.	.....	-----	-----	-----	E....	100
.							
LIP_RHIMI	-GHALNATSY	PDSVVQAMSI	----DGG-IR	AATSQEINEL	TYTTLSANS		121
LIP_RHIDL	GGMTLDLPSD	APPISLSSST	NSASDGGKVV	AATTAQIQEF	TKYAGIAATA		150
ABSIDIA	-----	SVSAF-	SSSSTQDYRI	-----	-ASEAEIKAH	TFYTALSANA	102
MDLA_PENCA	-----	-----	-----	-----	-VSTSELQDF	EFWVQYAAAS	46
Humicola	-----	-----	-----	-----	-VSQDLFNQF	NLFAQYSAAA	42
Consensus	-----	.....	-----	-----	-AS..EI..F	T.Y...S.A.A	150
.							
LIP_RHIMI	YC---RTVIP	GATWDCI--H	C-DA-FEDLK	IIXTWS-TLI	YDTNAMVARG		163
LIP_RHIDL	YC---RSVVP	GNKWDCV--Q	C-QKWVPOGK	IITTFI-SLL	SDTINGYVLR		193
ABSIDIA	YC---RTVIP	GGRWSCP--H	C-GV-ASNLO	ITKTFS-TLI	TDTNVLVAVG		144
MDLA_PENCA	YYEADYTAQV	GDKLSCSKGN	CPEVEATGAT	VSYDFSDSTI	TDTAGYIADV		96
Humicola	YCGKNDAPA	GTNITCTONA	CPEVEKADAT	FLYSFEDSGV	GDVTGFLALD		92
Consensus	YC---RTV.P	G..W.C.--	C-.V...D..	I..TFS-SLI	.DTNG.VA..		200
.							
LIP_RHIMI	DSEKTIYIVF	RGSSSIRNWI	ADLTFVPVSY	PPV-SGKVVH	KGFLDSYGEV		212
LIP_RHIDL	DKQKTIYLVF	RGINSFRSAI	TDIVNFSQDY	KPV-KGAKVH	AGFLSSYEQV		242
ABSIDIA	EKEKTIYVVF	RGSSSIRNWI	ADIVFVPVNY	PPV-NGAKVH	KGFLDSYNEV		193
MDLA_PENCA	HTNSAVLAF	RGSSSIRNWI	ADATF-VHFN	PGLCDGCLAE	LGFWSSHWLV		145
Humicola	NTWKLIVLSF	RGSSSIRNWI	GNLNFDLKEI	NDICSGCRGH	DGFTSSWPSV		142
Consensus	...KTIYLVF	RG.S.SIRNWI	AD...F...Y	PPV-.G.KVH	.GFLSSY..V		250
.							
LIP_RHIMI	QNELVATVLD	QFKQYPSYKV	AVTGHSLGGA	TALLCALDLY	QREGLSSSN		262
LIP_RHIDL	VNDYFPVVQE	QLTAHPTTYV	AVTGHSLGGA	QALLAGMDLY	QREPRLSPKN		292
ABSIDIA	QDKLVAEVKA	QLDRHPGYKI	AVTGHSLGGA	TAVLSALDLY	HHGH----AN		239
MDLA_PENCA	RDDIYKELRE	VVAQNPNYEL	AVTGHSLGGA	VATLAATDLR	GKGYP----S		191
Humicola	ADTLRQKVED	AVREHPDYRV	AVTGHSLGGA	LATVAGADLR	GNGY----D		187
Consensus	.D.L...V..	Q...HP.YKV	AVTGHSLGGA	.A.LAA.DLY	..G.....N		300
.							
LIP_RHIMI	LFLYTQQQPR	VGNPAFANYV	VST-GIPYRR	TVNERDIVPH	LPPAAFGLFH		311
LIP_RHIDL	LSIFTVGGPR	VGNPTFAYTV	EST-GIPFQR	TVHKRDIVPH	VPPQSFGLFH		341
ABSIDIA	IEIYTQQQPR	IGTAPAFANYV	IGT-KIPYQR	LVHERDIVPH	LPPGAFGLFH		288
MDLA_PENCA	AKLYAYASPR	VGNAAALAKYI	TAQ--GNNFR	FTHTNDPVPK	LPLLSMGYVH		239
Humicola	IDVFSYGAPR	VGNRAFAEFL	TVQEGGTLYR	ITHTNDIVPR	LPPREFGYSH		237
Consensus	...YT.G.PR	VGNPAFA.YV	..T-GIP..R	.VH.RDIVPH	LPP..FGFLH		350

Fig. 3 (a)

SUBSTITUTE SHEET (RULE 26)

LIP_RHIMI	AGEEYWITDN	SPETVQVC-T	SDLET----	S	DCSNSIVP-F	TSVLDHLSYF	355
LIP_RHIDL	PGVESWIKSG	TSN-VQIC-T	SEIET----	K	DCSNSIVP-F	TSILDHLSYF	384
ABSIDIA	AGEEFWIMKD	SSLRV--C-P	NGIET----	D	NCSNSIVP-F	TSVIDHLSYL	330
MDLA_PENCA	VSPEYWITSP	NNATVSTSDI	KVIDGDVDFD	GNTGTGLPLL	TDFEAHIWYF		289
Humicola	SSPEYWIKSG	TLVPVTRNDI	VKIEG---ID	ATGGNNQPNI	PDIPAHLWYF		294
Consensus	.G.EYWI.S.	....V..C-	..IET----	D	.CSNSIVP-F	TS..DHLSYF	400

LIP_RHIMI	GIN---TGLC	T-----	363
LIP_RHIDL	DIN---EGSC	L-----	392
ABSIDIA	DMN---TGLC	L-----	338
MDLA_PENCA	VQVDAGKGPC	LPFKRV	305
Humicola	GLI----GTC	L-----	291
Consensus	..N---.G.C	L-----	416

Fig. 3 (b)

ABSIDIA	M-----ESHF	VLLLAVFIC	MCSVSGVPL-	-----	-----	QIDP	28
LIP_RHIMI	MV-LKQRANY	LGF-LIVFFT	AFLVEAVPI-	-XRQSNSTV-	-----	DSLPP	40
LIP_RHIDL	MVSFISISQG	VSLCLLVSSM	MLGSSAVPVS	GKSGSSNTAV	SASDNEALPP		50
Consensus	MV-....S..	V.L.L.VF..	M..VSAVP.-	-X..S..T.-	-----	LPP	50
.							
ABSIDIA	-RDDKSYVPE	QYPLKVN---	-----	-----	GPLP	EGVSVIQGYC	58
LIP_RHIMI	LIPSRTSAPS	SSPSTTDPEA	-P-AM-----	---	SRNGPLP	S--DVEIKY-	77
LIP_RHIDL	LISSRCAPPS	NKGSKSDLQA	EPYNMQKNTB	WYESHGGMLT	SIGKRDDNLV		100
Consensus	LI.SR...PS	..PSK.D..A	-P-.M-----	---	S..GPLP	S...V...Y.	100
.							
ABSIDIA	ENCTHYPEKN	SVSAPSSSST	----QD--YR	IASEAEIKAH	TFYTALSANA		102
LIP_RHIMI	-GMALNATSY	POSVVQAMSI	----DGG-IR	AATSQEINEL	TYTTLSANS		121
LIP_RHIDL	GQNTLDLPSD	APPISLSST	NSASDGGKVV	AATTAQIQEF	TKYAGIAATA		150
Consensus	.GML...S.	..S...SSST	----DGG--R	AAT.AEI.E.	T.YT.LSANA		150
.							
ABSIDIA	YCRTVIPGGR	WSPHCGV-A	SNLQITKTFB	TLITDQWLV	AVGEKEKTIY		151
LIP_RHIMI	YCRTVIPGAT	WDCIHCA-T	EDLKIITKWS	TLIYDINAMV	ARGDSEKTIY		170
LIP_RHIDL	YCRSVVPGNK	WDCVQCQKVV	PDGKIITTFB	SLLSDINGYV	LRSDKQKTIY		200
Consensus	YCRTVIPG..	WDC.HC...-	.DLKIITKTFB	TLI.DIN..V	ARGDREKTIY		200
.							
ABSIDIA	VVFRGTSSIR	NAIADIVFVP	VYPPVNGAK	VHXGFSDSYN	EVQDKLVAEV		201
LIP_RHIMI	IVFRGSSSIR	NWIADLTFVP	VSYPVSGTK	VHXGFSDSYG	EVQNELVATV		220
LIP_RHIDL	LVFRGTNSFR	SAITDIVTFP	SDYKPVKGAK	VHAGFLSSYE	QVVNDYFPVV		250
Consensus	.VFRGTSSIR	NAIADIVFVP	V.YPPV.GAK	VHXGFSDSY.	EVQN.LVA.V		250
.							
ABSIDIA	KAQLDRHPGY	KVAVTGHSLG	GATAVLSALD	LYHHGH----	ANIEIYTQGG		247
LIP_RHIMI	LDQFKQYPSY	KVAVTGHSLG	GATALLCALD	LYQREGLSS	SNLFLYTQGG		270
LIP_RHIDL	QEQLTAHPTY	KVAVTGHSLG	GAQALLAGMD	LYQREPLSP	KNLSIFTVGG		300
Consensus	..QL...HP.Y	KV.VTGHSLG	GATALL.ALD	LYQRE...LS.	.NL.IYTQGG		300
.							
ABSIDIA	PRIGTPAFAN	YVIGTKIPYQ	RTVHERDIVP	HLPPGAFGFL	HAGEEFWIMK		297
LIP_RHIMI	PRVGOPAFAN	YVSTGIPYR	RTVHERDIVP	HLPPAAFGL	HAGEEYWITD		320
LIP_RHIDL	PRVGNPTFAY	YVESTGIPFQ	RTVHERDIVP	HVPPQSFGL	HPGVESWIKS		350
Consensus	PRVG.PAFAN	YV.STGIPYQ	RTVHERDIVP	HLPP.AFGFL	HAGEE.WI..		350
.							
ABSIDIA	DSSLRV--CP	NGIETDNCN	SIVPFTSVLD	HLSYLDINTG	LCL 318		
LIP_RHIMI	NSPETVQVCT	SDLETSDCN	SIVPFTSVLD	HLSYFGINTG	LCT 363		
LIP_RHIDL	GTSN-VQICT	SEIETKDCN	SIVPFTSILD	HLSYFDINEG	SCL 392		
Consensus	.SS..VQ.CT	S.IET.DCN	SIVPFTSVLD	HLSYFDINTG	LCL 393		

Fig. 3 (c)

Humicola	MRSSL--VLF	FVSAWT-ALA	SPIR-PEVSQ	DLFNQFNLFA	QYSAAAYCGX	46
MDLA_PENCA	MRLSFFTALS	AVASLGYALP	GKLQSTDVST	SELDQFEFWV	QYAAASYIEA	50
Consensus	MR.S....L.	.V.....AL.	.....R.VS.	....QF....	QY.AA.Y...	50
	.. . . .	.. . . .	.. . . .	.. . . .	.. . . .	
Humicola	NNDAPAGTNI	TCTGNACPEV	EKADATFLYS	FEDSGVGDVT	GFLALDNTNK	96
MDLA_PENCA	DYTAQVGDKL	SCSKGNCPEV	EATGATVSYD	FSOSTITDTA	GYIAVDHTNS	100
Consensus	...A..G...	.C....CPEV	E...AT..Y.	F.DS...D..	G..A.D.TN.	100
	.. . . .	.. . . .	.. . . .	.. . . .	.. . . .	
Humicola	LIVLSFRGSR	SIENWIGNLN	FDLKEINDIC	SGCRGHGFT	SSWRSVADTL	146
MDLA_PENCA	AVVLAFRGSY	SVRNWVADAT	F-VHTNPGLC	DCCLAELGFV	SSWKLVRDDI	149
Consensus	..VL.FRGS.	S..NW.....	F.....C	.GC....GF.	SSW..V.D..	150
	.. . . .	.. . . .	.. . . .	.. . . .	.. . . .	
Humicola	RQKVEDAVRE	HPDYRVVFTG	HSLGGALATV	AGADLRGNCY	-DIDVFSYGA	195
MDLA_PENCA	IKELKEVVAQ	NPNYELVVVG	HSLCAAVATL	AATDLRGKGY	PSAKLYAYAS	199
Consensus	.....V..	.P.Y..V..G	HSLG.A.A.T.	A..DLRG.GY	.....Y..	200
	.. . . .	.. . . .	.. . . .	.. . . .	.. . . .	
Humicola	PRVGNRAFAE	FLTVQTCGTL	YRITHINDIV	PRLPPREFGY	SHSSPEYWIK	245
MDLA_PENCA	PRVGNAAALX	YITAQ--GNN	FRFTHINDPV	PKLPLLSMGY	VHVSPEYWIT	247
Consensus	PRVGN.A.A.	..T.Q..G..	.R.THIND.V	P.LP....GY	.H.SPEYWI.	250
	.. . . .	.. . . .	.. . . .	.. . . .	.. . . .	
Humicola	SGTLVPVTRN	DIVKIEG---	IDATGQNNQP	NIPDIPAHW	YFGLI----G	288
MDLA_PENCA	SPNWTVSTS	DIKVIDGDVS	FDGNTGTGLP	LLTDFEAIW	YFVQVDAGKC	297
Consensus	S.....V...	DI..I.G....	.D...G...P	...D..AH.W	YF.....C	300
	.. . . .	.. . . .	.. . . .	.. . . .	.. . . .	
Humicola	TCL-----	291				
MDLA_PENCA	PGLPFRV	305				
Consensus	..L.....	308				
	.. . . .					

Fig. 3 (d)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00105

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: C12N 15/10, C12Q 1/68 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C12N, C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9522625 A1 (AFFYMAX TECHNOLOGIES N.V.), 24 August 1995 (24.08.95), page 9, line 6 - line 8; page 78, line 16 - line 25, claim 12	1-2,5-6
A	----- -----	3-4,7-8
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<ul style="list-style-type: none"> <li>* Special categories of cited documents</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" other document but published on or after the international filing date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filing date but later than the priority date claimed</li> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</li> <li>"Z" document: member of the same patent family</li> </ul>		
Date of the actual completion of the international search		Date of mailing of the international search report
2 July 1998		03-07-1998
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  Patrick Andersson Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT  
Information on patent family members

09/06/98

International application No.  
PCT/DK 98/00105

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9522625 A1	24/08/95	AU 2971495 A	04/09/95
		CA 2182393 A	24/08/95
		CN 1145641 A	19/03/97
		EP 0752008 A	08/01/97
		JP 10500561 T	20/01/98
		US 5605793 A	25/02/97

-----

SSI  
.SE  
S.

.TVQ

**THIS PAGE BLANK (USPTO)**